Emerging treatments in chronic hepatitis B

Bibliography

• KANE M: Global programme for control ofhepatitis B infection. Vaccine (1995) 13:S47–S49.
   PubMed Web of Science ®Google Scholar
• GAY N, EDMUNDS W, BAH E, NELSON C: Estimating the global burden of hepatitis B. Geneva: World HealthOrganization. Department of Vaccines and Biologicals (2001).
   Google Scholar
• LEE WM: Hepatitis B virus infection. N. Engl. J. Med. (1997) 337:1733–1745.
   PubMed Web of Science ®Google Scholar
• LIAW YE TAI DI, CHU CM, CHEN TJ: The development of cirrhosis in patients with chronic type B hepatitis: a prospective study. Hepatology (1988) 8:493–496.
   PubMed Web of Science ®Google Scholar
• FATTOVICH G, BROLLO L, GIUSTINA G et al.: Natural-history and prognostic factors for chronic hepatitis type B. Gut (1991) 32:294–298.
   PubMed Web of Science ®Google Scholar
• WEISSBERG JI, ANDRES LL, SMITH CI et al.: Survival in chronic hepatitis B. An analysis of 379 patients. Ann. Intern. Med. (1984) 101:613–616.
   PubMed Web of Science ®Google Scholar
• DE JONGH FE, JANSSEN HLA, DE MAN RA, HOP WCJ, SCHALM SW, VAN BLANKENSTEIN M: Survival and prognostic indicators in HBsAg-positivecirrhosis of the liver. Gastroenterology (1992) 103: 1630–1635.
   Google Scholar
• REALDI G, FATTOVICH G, HADZIYANNIS S et al.: Survival and prognostic factors in 366 patients with compensated cirrhosis type B: a multicenter study. J. Hepatol. (1994) 21:656–666.
   PubMed Web of Science ®Google Scholar
• BEASLEY RP: The major etiology of hepatocellular carcinoma. Cancer (1988) 61:1942–1956.
   PubMed Web of Science ®Google Scholar
• PARKIN DM, BRAY F, FERLAY J, PISANI P: Estimating the world cancer burden: Globocan 2000. hat. J. Cancer (2001) 94:153–156.
   PubMed Web of Science ®Google Scholar
• EASL International consensus conference on hepatitis B. Hepatol. (2003)39\(Suppl. 1):53–525.
   Google Scholar
• ••This review provides the summary of aninternational consensus conference on hepatitis B sponsored by EASL and held in September 2002.
   Google Scholar
• LOK AS, HEATHCOTE EJ, HOOFNAGLE JH: Management of hepatitis B: 2000-summary of a workshop. Gastroenterology (2001) 120: 1828–1853.
   Google Scholar
• •This review provides the summary of a 3-day workshop on the management of hepatitis B sponsored by the NIDDK and AGA and held in September 2000.
   Google Scholar
• HADZIYANNIS SJ,VASSILOPOULOS D: Hepatitis B e antigen-negative chronic hepatitis B. Hepatology (2001) 34:617–624.
   PubMed Web of Science ®Google Scholar
• •A review focused on the pathogenesis of HBeAg-negative chronic hepatitis B.
   Google Scholar
• LOK ASF, MCMAHON BJ: Chronic hepatitis B. Hepatology (2001) 34:1225–1241.
   PubMed Web of Science ®Google Scholar
• HOOFNAGLE JH, DUSHEIKO GM, SEEFF LB, JONES A, WAGGONER JG, BALES ZB: Seroconversion from hepatitis B e antigen to antibody in chronic type B hepatitis. Ann. Intern. Med. (1981) 94:744–748.
   PubMed Web of Science ®Google Scholar
• FATTOVICH G, RUGGE M, BROLLO L et al.: Clinical, virologic and histologic outcome following seroconversion from HBeAg to anti-HBe in chronic hepatitis type B. Hepatology (1986) 6:167–172.
   PubMed Web of Science ®Google Scholar
• YANG H-I, LU S-N, LIAW Y-F et al.: Hepatitis B e antigen and the risk of hepatocellular carcinoma. N Engl. I Med. (2002) 347:168–174.
   PubMed Web of Science ®Google Scholar
• HADZIYANNIS SJ: Hepatitis B e antigen negative chronic hepatitis B: from clinical recognition to pathogenesis and treatment. Vic Hep. Rev (1995) 1:7–36.
   Google Scholar
• HUNT CM, MCGILL JM, ALLEN ML, CONDREAY LD: Clinical relevance of hepatitis B virus mutations. Hepatology (2000) 31:1037–1044.
   PubMed Web of Science ®Google Scholar
• BONINO F, ROSINA F, RIZZETTO M et al.: Chronic hepatitis in HBsAg carriers with serum HBV-DNA and anti-HBe. Gastroenterology (1986) 90:1268–1273.
   PubMed Web of Science ®Google Scholar
• BRUNETTO MR, GIARIN M, OLIVERI F et al.: Wild type and e antigen-minus hepatitis B virus in course of chronic hepatitis. Proc. Nati Acad. ScL USA (1991) 88:4186–4190.
   PubMed Web of Science ®Google Scholar
• NAOUMOV NV, SCHNEIDER R, GROTZINGER T et al.: Precore mutant hepatitis B virus infection and liver disease. Gastroenterology (1992) 102:538–543.
   PubMed Web of Science ®Google Scholar
• LAI ME, SOLINAS A, MAZZOLENI AP et al.: The role of pre-core hepatitis B virus mutants on the long-term outcome of chronic hepatitis B virus hepatitis. A longitudinal study. J. Hepatol. (1994) 20:773–781.
   PubMed Web of Science ®Google Scholar
• WONG DKH, CHEUNG AM, O'ROURKE K, NAYLOR CD, DETSKY AS, HEATHCOTE J: Effect of alpha-interferon in patients with hepatitis B e antigen-positive chronic hepatitis B. A meta-analysis. Ann. Intern. Med. (1993) 119:312–323.
   PubMed Web of Science ®Google Scholar
• BROOK MG, KARAYIANNIS P, THOMAS HC: Which patients with chronic hepatitis B virus infection will respond to alpha-interferon therapy? A statistical analysis of predictive factors. Hepatology (1989) 10:761–763.
   PubMed Web of Science ®Google Scholar
• PAPATHEODORIDIS GV, HADZIYANNIS SJ: Current management of chronic hepatitis B. Aliment. Pharmacol. Then (2004) 19:25–37.
   PubMed Web of Science ®Google Scholar
• •A review on the management of chronic hepatitis B in early 2004.
   Google Scholar
• PAPATHEODORIDIS GV, HADZIYANNIS SJ: Diagnosis and management of pre-core mutant chronic hepatitis B. J. Viraillepat. (2001) 8:311–321.
   Google Scholar
• BRUNETTO MR, OLIVERI F, COLOMBATTO P, CAPALBO M, BARBERA C, BONINO F: Treatment of chronic anti-HBe-positive hepatitis B with interferon-alpha. J. Hepatol. (1995) 22:42–44.
   PubMed Web of Science ®Google Scholar
• HADZIYANNIS SJ, PAPATHEODORIDIS GV, VASSILOPOULOS D: Treatment of HBeAg-negative chronic hepatitis B. Semin. Liver Dis. (2003) 23:81–88.
   PubMed Web of Science ®Google Scholar
• •A review on the goals, indications and efficacy of therapeutic options for HBeAg-negative chronic hepatitis B in early 2003.
   Google Scholar
• HADZIYANNIS SJ, PAPATHEODORIDIS GV: Treatment of HBeAg negative chronic hepatitis B with new drugs (adefovir and others). Hepatol. (2003) 39\(Suppl. 1):5172–5176.
   Google Scholar
• KARAYIANNIS P: Hepatitis B virus: old,new and future approaches to antiviral treatment. Antimicrob. Chemother. (2003) 51:761–785.
   Web of Science ®Google Scholar
• HOOFNAGLE JH, DI BISCEGLIE AM: The treatment of chronic viral hepatitis. N Engl. J. Med. (1997) 336:347–356.
   PubMed Web of Science ®Google Scholar
• KORENMAN J, BAKER B, WAGGONER J, EVERHART JE, DI BISCEGLIE AM, HOOFNAGLE JH: Long-term remission of chronic hepatitis B after alpha-interferon therapy. Ann. Intern. Med. (1991) 114:629–634.
   PubMed Web of Science ®Google Scholar
• NIEDERAU C, HEINTGES T, LANGE S et al.: Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B. N Engl. I Med. (1996) 334:1422–1427.
   PubMed Web of Science ®Google Scholar
• VAN NUNEN AB, HANSEN BE, SUH DJ et al.: Durability of HBeAg seroconversion following antiviral therapy for chronic hepatitis B: relation to type of therapy and pretreatment serum hepatitis B virus DNA and alanine aminotransferase. Gut (2003) 52:420–424.
   PubMed Web of Science ®Google Scholar
• KAO J-H, WU N-H, CHEN P-J, LAI M-Y, CHEN D-S: Hepatitis B genotypes and the response to interferon therapy. Hepatol. (2000) 33:998–1002.
   Web of Science ®Google Scholar
• WAI CT, CHU C-J, HUSSAIN M, LOK ASF: HBV genotype B is associated with better response to interferon therapy in HBeAg(+) chronic hepatitis thangenotype C. Hepatology (2002) 36:1425–1430.
   PubMed Web of Science ®Google Scholar
• MANESIS EK, HADZIYANNIS SJ: Interferon-alpha treatment and retreatment of hepatitis B e antigen-negative chronic hepatitis B. Gastroenterology (2001) 121:101–109.
   PubMed Web of Science ®Google Scholar
• •The largest study of standard interferon therapy in HBeAg-negative chronic hepatitis B.
   Google Scholar
• LAMPERTICO P, DEL NINNO E, VIGANO M et al.: Long-term suppression of hepatitis B e antigen-negative chronichepatitis B by 24-month interferon therapy. Hepatology (2003) 37:756–763.
   PubMed Web of Science ®Google Scholar
• ZHANG X, ZOULIM F,HABERSETZER F, XIONG S, TREPO C: Analysis of hepatitis B virus genotypes and pre-core region variability during interferon treatment of HBe antigen negative chronic hepatitis B. Med. Virol. (1996) 48:8–16.
   PubMed Web of Science ®Google Scholar
• ERHARDT A, REINEKE U,BLONDIN D et al.: Mutations in the core promoter and response to interferon treatment in chronic replicative hepatitis B. Hepatology (2000) 31:716–725.
   PubMed Web of Science ®Google Scholar
• CARRENO V, MARCELLIN P, HADZIYANNIS S et al.: Retreatment of chronic hepatitis B e antigen-positive patients with recombinant interferon alfa 2a. The European Concerted Action on Viral Hepatitis (EUROHEP). Hepatology (1999) 30:277–282.
   PubMed Web of Science ®Google Scholar
• VINAYEK R, SHAKIL 0: Adverse events associated with interferon-alfa therapy in patients with chronic viral hepatitis. Viral Hep. Rev. (1997) 3:167–177.
   Web of Science ®Google Scholar
• WONG JB, KOFF RS, TINE F, PAUKER SG: Cost-effectiveness of interferon-alpha 2b treatment for hepatitis B e antigen-positive chronic hepatitis B. Ann. Intern. Med. (1995) 122:664–675.
   PubMed Web of Science ®Google Scholar
• JARVIS B, FAULDS D: Lamivudine. A review of its therapeutic potential in chronic hepatitis B. Drugs (1999) 58:101–141.
   PubMed Web of Science ®Google Scholar
• LAI C-L, CHIEN R-N, LEUNG NWY et al.: A one-year trial of lamivudine for chronic hepatitis B. N EngL I Med. (1998) 339:61–68.
   PubMed Web of Science ®Google Scholar
• DIENSTAG JL, SCHIFF ER,WRIGHT TL et al.: Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl. Med. (1999) 341:1256–1263.
   PubMed Web of Science ®Google Scholar
• DIENSTAG JL, SCHIFF ER,MITCHELL M et al.: Extended lamivudine retreatment for chronic hepatitis B: maintenance of viral suppression after discontinuation of therapy. Hepatology (1999) 30:1082–1087.
   PubMed Web of Science ®Google Scholar
• SCHIFF E, CIANCIARA J,KARAYALCIN S et al.: Durable HBeAg and HBsAg seroconversion after lamivudine for chronic hepatitis B. Hepatol. (2000) 32\(Suppl. 2):99.
   Web of Science ®Google Scholar
• CHANG TT, LAI CL, LIAW YF et al.: Incremental increases in HBeAg seroconversion and continued ALT normalisation in Asian chronic HBV(CHB) patients treated with lamivudine for four years. Antivic Therapy (2000)5 (Suppl. 1):44.
   Google Scholar
• SONG B-C, SUH DJ, LEE HC, CHUNG Y-H, LEE YS: Hepatitis B e antigen seroconversion after lamivudine therapy is not durable in patients with chronic hepatitis B in Korea. Hepatology (2000) 32:803–806.
   PubMed Web of Science ®Google Scholar
• LEUNG NW, LIAW Y-F, CHANG T-T et al.: Durable HBeAg response in Chinese patients treated with lamivudine. Hepatology (2001) 34:348A.
   Google Scholar
• LEUNG NWY, LAI CL, CHANG TT et al.: Three year lamivudine therapy in chronic HBV. Hepatol. (1999)30\(Suppl. 1):59.
   Google Scholar
• LIAW Y-F, LEUNG NWY, CHANG T-T et al.: Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Gastroenterology(2000) 119: 172–180.
   Google Scholar
• TASSOPOULOS NC, VOLPES R, PASTORE G et al.: Efficacy of lamivudine in patients with hepatitis B e antigen-negative/hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B. Hepatology (1999) 29:889–896.
   PubMed Web of Science ®Google Scholar
• HADZIYANNIS SJ,PAPATHEODORIDIS GV, DIMOU E, LARAS A, PAPAIOANNOU C: Efficacy of long-term lamivudine monotherapy in patients with HBeAg negative chronic hepatitis B. Hepatology (2000) 32:847–851.
   PubMed Web of Science ®Google Scholar
• PAPATHEODORIDIS GV, DIMOU E, LARAS A, PAPADIMITROPOULOS V, HADZIYANNIS SJ: Course of virologic breakthroughs under long-term lamivudine in HBeAg-negative precore mutant HBV liver disease. Hepatology(2002) 36: 219–226.
   Google Scholar
• TASSOPOULOS NC, VOLPES R, PASTORE G et al.: Post lamivudine treatment follow up of patients with HBeAg negative chronic hepatitis B. Hepatol. (1999) 30\(Suppl. 1):117.
   Google Scholar
• SANTANTONIO T, MAZZOLA M, IACOVAZZI T, MIGLIETTA A, GUASTADISEGNI A, PASTORE G: Long-term follow-up of patients with anti-HBe/HBV DNA-positive chronic hepatitis B treated for 12 months with lamivudine. .1. Hepatol. (2000) 32:300–306.
   Google Scholar
• DI MARCO V, MARZANO A,LAMPERTICO P et al.: The course of anti-HBe/HBV-DNA positive chronic liver disease during long-term lamivudinetreatment. Hepatol. (2003) 38 (Suppl. 2):25.
   PubMed Web of Science ®Google Scholar
• PAPATHEODORIDIS GV, DIMOU E, PAPADIMITROPOULOS V: Nucleoside analogues for chronic hepatitis B: antiviral efficacy and viral resistance. Am. Gastmenterol (2002) 97:1618–1628.
   PubMed Web of Science ®Google Scholar
• ALLEN MI, DESLAURIERS M, ANDREWS CW et al.: Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Lamivudine Clinical Investigation Group. Hepatology (1998) 27:1670–1677.
   PubMed Web of Science ®Google Scholar
• LAU DTY, KHOKHAR ME DOO E et al.: Long-term therapy of chronic hepatitis B with lamivudine. Hepatology (2000) 32:828–834.
   PubMed Web of Science ®Google Scholar
• DIENSTAG JL, GOLDIN RD, HEATHCOTE EJ et al.: Histologic outcome during long-term lamivudine therapy. Gastroenterology (2003) 124:105–117.
   PubMed Web of Science ®Google Scholar
• ••An important study showing the effect oflamivudine-resistant HBV mutants on the liver histology of patients with HBeAg-positive chronic hepatitis B under long-term lamivudine therapy.
   Google Scholar
• CUNDY KC: Clinical pharmacokinetics of the antiviral nucleotide analogues cidofovir and adefovir. Clin. Pharmacokinet. (1999) 36:127–143.
   PubMed Web of Science ®Google Scholar
• HADZIYANNIS SJ,PAPATHEODORIDIS GV: Adefovir dipivoxil in the treatment of chronic hepatitis B virus infection. Expert Rev. Anti-infect. The]: (2004) 2:475–483.
   PubMedGoogle Scholar
• KNIGHT W, HAYASHI S, BENHAMOU Y et al.: Dosing guidelines for adefovir dipivoxil in the treatment of HBV infected patients with renal or hepatic impairment. Hepatol. (2002)36(Suppl. 1):136.68. MARCELLIN P, CHANG TT, LIM SG et al.: Adefovir dipivoxil for the treatment of hepatitis B antigen-positive chronic hepatitis B. N Engl. I Med. (2003) 348:808–816.
   PubMed Web of Science ®Google Scholar
• ••This randomised, multi-centre, placebo-controlled trial demonstrated the safety and efficacy of a 48-week course with adefovir dipivoxil in patients with HBeAg-positive chronic hepatitis B.
   Google Scholar
• HEATHCOTE E, JEFFERS L, PERRILLO R et al.: Sustained antiviral response and lack of viral resistance with long term adefovir dipivoxil (ADV) therapy in chronic HBV infection. I Hepatol. (2002) 36\(Suppl. 1):110–111.
   Web of Science ®Google Scholar
• HADZIYANNIS SJ,TASSOPOULOS NC, HEATHCOTE EJ et al.: Adefovir dipivoxil for the treatment of hepatitis B antigen-negative chronic hepatitis B. N Engl. J. Med. (2003) 348:800–807.
   PubMed Web of Science ®Google Scholar
• ••This randomised, multi-centre, double-blind, placebo-controlled trial demonstrated the safety and efficacy of a 48-week course with adefovir dipivoxil in patients with HBeAg-negative chronic hepatitis B.
   Google Scholar
• HADZIYANNIS SJ, TASSOPOULOS N, HEATHCOTE E et al.: Two year results from a double-blind, randomized, placebo-controlled study of adefovir dipivoxil (ADV) for presumed precore mutant chronic hepatitis B. J. Hepatol. (2003) 38\(Suppl. 2):143.
   Web of Science ®Google Scholar
• HADZIYANNIS SJ, TASSOPOULOS N, CHANG TT et al.: Three year study of adefovir dipivoxil (ADV) demonstrates sustained efficacy in presumed precore mutant chronic hepatitis B (CHB) patients in a long term safety and efficacy study (LTES). Hepatol (2004) 40\(Suppl. 1):17.
   Web of Science ®Google Scholar
• •This study, recently presented as an abstract, showed the safety and sustained efficacy of 3 years therapy with adefovir dipvoxil in patients with HBeAg-negative chronic hepatitis B.
   Google Scholar
• XIONG S, YANG H, WESTLAND CE et al.: Resistance surveillance of HBeAg-chronic hepatitis B (CHB) patients treated for two years with adefovir dipivoxil (ADV).Hepatol (2003) 38\(Suppl. 2):182.
   Web of Science ®Google Scholar
• QI X, SNOW A, THIBAULT V et al.: Long-term incidence of adefovir dipivoxil (ADV) resistance in chronic hepatitis B (CHB) patients after 144 weeks of therapy.Hepatol (2004) 40\(Suppl. 1):20–21.
   Web of Science ®Google Scholar
• ANGUS P, VAUGHAN R, XIONG S et al.: Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase. Gastroenterology (2003) 125:292–297.
   PubMed Web of Science ®Google Scholar
• •The first study describing in detail the HBV mutations associated with resistance to adefovir dipivoxil.
   Google Scholar
• ZOULIM F, TREPO C, POYNARD T et al.: Adefovir dipivoxil (ADV) for the treatment of patients with chronic hepatitis B (CHB) failing lamivudine (LAM) therapy. Hepatol (2003) 38\(Suppl. 2):184.
   Web of Science ®Google Scholar
• PETERS MG, HANN HH, MARTIN P et al.: Adefovir dipivoxil alone or in combination with lamivudine in patientswith lamivudine-resistant chronic hepatitis B. Gastroenterology (2004) 126:91–101.
   PubMed Web of Science ®Google Scholar
• •A study showing that adefovir dipivoxil monotherapy may have the same efficacy with the combination of adefovir dipivoxil and lamivudine in the treatment of lamivudine-resistant patients with HBeAg-positive chronic hepatitis B.
   Google Scholar
• WESTLAND CE, YANG H, NAMIMI H et al.: Comparison of anti-HBV activity of adefovir against different lamivudine-resistant HBV strains in vitro and in liver transplant patients. Hepatology (2001) 34:446A.
   Google Scholar
• LEBRAY P, VALLET-PICHARD A, MICHEL ML et al.: Immunomodulatory drugs and therapeutic vaccine in chronic hepatitis B infection. Hepatol (2003) 39\(Suppl. 1):5151–5159.
   Google Scholar
• KUHNS M, MCNAMARA A, MASON A, CAMPBELL C, PERRILLO R: Serum and liver hepatitis B virus DNA in chronic hepatitis B after sustained loss of surface antigen. Gastroenterology (1992) 103:1649–1656.
   PubMed Web of Science ®Google Scholar
• KOMORI M, YUKI N, NAGAOKA T et al.: Long-term clinical impact of occult hepatitis B virus infection in chronic hepatitis B patients. Hepatol (2001) 35:798–804.
   Web of Science ®Google Scholar
• PAPATHEODORIDIS GV, MANESIS E, HADZIYANNIS SJ: The long-term outcome of interferon-a treated and untreated patients with HBeAg-negative chronic hepatitis B. Hepatol (2001) 34:306–313.
   Web of Science ®Google Scholar
• ••An important study showing the effect ofthe IFN therapy and particularly of the type of response to IFN therapy on the long-term outcome of patients with HBeAg-negative chronic hepatitis B.
   Google Scholar
• NOWAK MA, BONHOEFFER S, HILL AM, BOEHME R, THOMAS HC, MCDADE H: Viral dynamics in hepatitis B virus infection. Proc. Nati Acad. Sci. USA (1996) 93:4398–4402.
   PubMed Web of Science ®Google Scholar
• COOKSLEY WG, PIRATVISUTH T, LEE SD et al.: Peginterferon alpha-2a (40 kDa): an advance in the treatment of hepatitis B e antigen-positive chronic hepatitis B. I Viral Hepat.(2003) 10:298–305.
   PubMed Web of Science ®Google Scholar
• •An important Phase II study evaluating for the first time the efficacy of PEG-INF-a2. in HBeAg-positive chronic hepatitis B.
   Google Scholar
• SUNG JJY, CHAN HLY, HUT AY et al.: Combination of pegylated interferon and lamivudine is superior to lamivudine monotherapy in the treatment of chronic hepatitis B - a randomized trial. Hepatol (2003) 38\(Suppl. 2):33.
   Web of Science ®Google Scholar
• MARCELLIN P, LAU GK, BONINO F et al.: Peginterferon-alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N Eng. I Med. (2004) 351:1206–1217.
   PubMed Web of Science ®Google Scholar
• ••An important study showing that, in thetreatment of HBeAg-negative chronic hepatitis B, the efficacy of PEG-INF-a2. alone is similar to that of the combination of PEG-INF-a2. and lamivudine, both being superior than lamivudine alone.
   Google Scholar
• TORRESI J, LOCARNINI S: Antiviral chemotherapy for the treatment of hepatitis B virus infections. Gastroenterology (2000) 118(Suppl.):S83–S103.
   Google Scholar
• HART GJ, ORR DC, PENN CR et al.: Effects of ( ) 2' deoxy 3' thiacytidine (3TC) Y-triphosphate on human immunodeficiency virus reverse transcriptase and mammalian DNA polymerases alpha, beta, and gamma. Antimicrob. Agents Chemother (1992) 36:1688–1694.
   PubMed Web of Science ®Google Scholar
• TUTTLEMAN JS, POURCEL C, SUMMERS J: Formation of the pool of covalently closed circular viral DNA in hepadnavirus-infected cells. Cell (1986) 47:451–460.
   PubMed Web of Science ®Google Scholar
• MORALEDA G, SAPUTELLI J, ALDRICH CE, AVERETT D, CONDREAY L, MASON WS: Lack of effect of antiviral therapy in nondividing hepatocyte cultures on the closed circular DNA of woodchuck hepatitis virus. I. Vim/. (1997) 71:9392–9399.
   Google Scholar
• ARTS E, WAINBERG M: Mechanism of nucleoside analog antiviral activity and resistance during human immunodeficiency virus reverse transcription. Antimicrob. Agents Chemother. (1996) 40:527–540.
   PubMed Web of Science ®Google Scholar
• WERLE-LAPOSTOLLE B, BOWDEN S, LOCARNINI S et al.: Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy. Gastroenterology (2004) 126:1750–1758.
   PubMed Web of Science ®Google Scholar
• SHAW T, BOWDEN S, LOCARNINI S: Rescue therapy for drug resistant hepatitis B: another argument for combination chemotherapy? Gastroenterology (2004) 126:343–347.
   PubMed Web of Science ®Google Scholar
• NATIONAL INSTITUTE OF HEALTH CONSENSUS DEVELOPMENTCONFERENCE STATEMENT: Management of hepatitis C: 2002 - June 10–12, 2002. Hepatology (2002)36\(Suppl. 1):53–520.This review provides the summary of the consensus statement on the management of hepatitis C sponsored by the NIH and held in 2002.
   Google Scholar
• VAN ZONNEVELD M, VAN NUNEN AB, DE MAN RA, SCHALM SW, JANSSEN HLA: Chronic HBV treatment with one year of pegylated-interferon alpha-2b (PEG-IFN) has a comparable safety profile to short term conventional interferon alpha-2b.Hepatal (2003) 38\(Suppl. 2):179.
   PubMed Web of Science ®Google Scholar
• VAN ZONNEVELD M, ZONDERVAN P, DE MAN RA, SCHALM SW, JANSSEN HLA: Liver histology in chronic hepatitis B patients after 1 year of treatment with pegylated interferon interferon alpha-2b in combination with lamivudine or placebo. J. Hepatal (2004) 40\(Suppl. 0:132.
   PubMed Web of Science ®Google Scholar
• YAMANAKA G, WILSON T, INNAIMO S et al.: Metabolic studies on BMS-200475, a new antiviral compound active against hepatitis B virus. Antimicrob. Agents Chemother. (1999) 43:190–193.
   PubMed Web of Science ®Google Scholar
• NEVENS F, DE MAN RA, CHUA D et al.: Effectiveness of a low dose of entecavir in treating recurrent viremia in chronic hepatitis B. Hepatology (2000) 32(Suppl.):377A.
   Google Scholar
• LAI C-L, ROSMAWATI M, LAO J et al.:Entecavir is superior to lamivudine in reducing hepatitis B virus DNA in patients with chronic hepatitis B. Gastroenterology (2002) 123:1831–1838.
   PubMed Web of Science ®Google Scholar
• •An interesting study on the antiviral efficacy of entecavir.
   Google Scholar
• DE MAN RA, WOLTERS L, NEVENS F et al.: A study of oral entecavir given for 28 days in both treatment-naive and pre-treated subjects with chronic hepatitis. Hepatology (2000) 32(Suppl.):376A.
   Google Scholar
• TASSOPOULOS N, HADZIYANNIS S, CIANCIARA J et al.: Entecavir is effective in treating patients with chronic hepatitis B who have failed lamivudine therapy. Hepatology (2001) 34:340A.
   PubMedGoogle Scholar
• CHANG T-T, HADZIYANNIS S, CIANCIARA J et al.: Sustained viral load and ALT reduction following 48 weeks of entecavir treatment in subjects with chronic hepatitis B who have failed lamivudine. Hepatology (2002) 36:300A.
   Web of Science ®Google Scholar
• COLONNO R, ROSE R: Genotypic analysis following 48 week entecavir treatment of chronic HBV subjects failing lamivudine suggests sustained susceptibility and lack of resistance development. Hepatology (2002) 36:644A.
   Google Scholar
• GISH R, CHANG TT, HADZIYANNIS S et al.: Sustained viral load and ALT reduction following 48 weeks of entecavir treatment in HBeAg-negative and -positive patients with chronic hepatitis B who have failed prior lamivudine therapy. J. Hepatal (2003) 38\(Suppl. 2):32–33.
   PubMed Web of Science ®Google Scholar
• KORBA BE, SCHINAZI RE COTE P, TENNANT BC, GERIN JL: Effect of oral administration of emtricitabine on woodchuck hepatitis virus replication in chronically infected woodchucks. Antimicrob. Agents Chemother: (2000) 44:1757–1760.
   PubMed Web of Science ®Google Scholar
• LADNER SK, MILLER TJ, OTTO MJ, KING RW: The hepatitis B virus M539V polymerase variation responsible for 3TC resistance also confers cross-resistance to other nucleoside analogues. Antivir: Chem. Chemothei: (1998) 9:65–72.
   PubMed Web of Science ®Google Scholar
• WANG C, CORREY L, LEUNG N et al.: Antiviral activitry of 48 weeks of emtricitabine (FTC) treatment in patients with HBeAg negative/HBV DNA positive chronic hepatitis B (CHB). Hepatology (2001) 34:323A.
   Web of Science ®Google Scholar
• CHU CK, MAT, SHANMUGANATHAN K et al.: Use of 2'-fluoro-5-methyl-beta-L-arabinofuranosyluracil as a novel antiviral agent for hepatitis B virus and Epstein-Barr virus. Antimicrob. Agents Chemother. (1995) 39:979–981.
   PubMed Web of Science ®Google Scholar
• CHU CK, BOUDINOT FD, PEEK SF et al.: Preclinical investigation of L-FMAU as an anti-hepatitis B virus agent. Alava: Thei: (1998) 3\(Suppl. 3):113–121.
   Google Scholar
• PEEK SF, COTE PJ, JACOB JR et al.: Antiviral activity of clevudine [L-FMAU, (1-(2-fluoro-5-methyl-beta, 1-arabinofuranosyl) uracil) I against woodchuck hepatitis virus replication and gene expression in chronically infected woodchucks (Marmara monax Hepatology (2001) 33:254–266.
   PubMed Web of Science ®Google Scholar
• ABDELHAMED AM, KELLEY CM, MILLER TG, FURMAN PA, CABLE EE, ISOM HC: Comparison of anti-hepatitis B virus activities of lamivudine and clevudine by a quantitative assay. Antimicrob. Agents Chemother. (2003) 47:324–336.
   PubMed Web of Science ®Google Scholar
• MARCELLIN P, MOMMEJA-MARIN H, SACKS SL et al.: A Phase II dose-escalating trial of clevudine in patients with chronic hepatitis B. Hepatology (2004) 40: 140–148.
   Google Scholar
• •An interesting Phase II study on the antiviral efficacy of clevudine.
   Google Scholar
• STANDRING DN, BRIDGES EG, PLACIDI L et al.: Antiviral beta-L-nucleosides specific for hepatitis B virus infection. Antivic Chem. Chemother: (2003) 12\(Suppl. 0:119–129.
   Google Scholar
• •A review focusing on the L-nucleosides as new anti-HBV agents.
   Google Scholar
• BRYANT ML, BRIDGES EG, PLACIDI L et al.: Antiviral L-nucleosides specific for hepatitis B virus infection. Antimicrob. Agents Chemother: (2001) 45:229–235.
   PubMed Web of Science ®Google Scholar
• DELANEY W, YANG H, MILLER M, GIBBS C, XIONG S: Lamivudine-resistant HBV is cross-resistant to L-dT and L-dC in vitro. J. Hepatal (2002) 36\(Suppl. 1):89.
   Google Scholar
• HOD GE RA: Telbivudinehorcitabine Idenix/Novartis. CLIFF. Opin. Investig. Drugs (2004) 5:232–241.
   PubMedGoogle Scholar
• LAI C-L, MYERS MW, POW DM et al.: Safe and potent suppression of hepatitis B virus (HBV) with L-deoxythymidine (LDT): results of a dose-escalation trial. Hepatology (2001) 34:321A.
   Google Scholar
• LAI C-L, LEUNG N, TEO EK et al.: International multicenter trial of LdT (telbivudine), alone and in combination with lamivudine, for chronic hepatitis B: an interim analysis. Hepatology (2002) 36:301A.
   Web of Science ®Google Scholar
• LAI C-L, LEUNG NWY, TEO E-K et al.: Results of a one-year international Phase IIb comparative trial of telbivudine,lamivudine, and the combination, in patients with chronic hepatitis B. Hepatology (2003) 38\(Suppl. 1):262A.
   Google Scholar
• BENHAMOU Y, POYNARD T: Treatment of chronic hepatitis B virus infection in patients co-infected with human immunodeficiency virus. J. Hepatal (2003) 39\(Suppl. 1):5194–5199.
   Google Scholar
• LESSELLS R, LEEN C: Management of hepatitis B in patients coinfected with the human immunodeficiency virus. Eui: Clin. Microbial Infect. Dis. (2004) 23:366–374.
   PubMed Web of Science ®Google Scholar
• BENHAMOU Y: Antiretroviral therapy and HIV/hepatitis B virus coinfection. Clin. Infect. Dis. (2004) 38\(Suppl. 2): S98–S103.
   PubMed Web of Science ®Google Scholar
• DORE GJ, COOPER DA, POZNIAK AL et al.: Efficacy of tenofovir disoproxil fumarate in antiretroviral therapy-naive and-experienced patients coinfected with HIV-1 and hepatitis B virus. .1. Infect. Dis. (2004) 189:1185–1192.
   Web of Science ®Google Scholar
• LERBAEK A, KRISTIANSEN TB, KATZENSTEIN TL et al.: Tenofovir treatment in an unselected cohort of highly antiretroviral experienced HIV positive patients. Scand J. Infect. Dis. (2004) 36:280–286.
   PubMed Web of Science ®Google Scholar
• BENHAMOU Y, BOCHET M, THIBAULT V et al.: Safety and efficacy of adefovir dipivwdl in patients co-infected with HIV-1 and lamivudine-resistant hepatitis B virus: an open-label pilot study. Lancet (2001) 358:718–723.
   PubMed Web of Science ®Google Scholar
• BILLICH A: Thymosin alphal. SciClone Pharmaceuticals. Cuir. Opin. Investig. Drugs (2002) 3:698–707.
   PubMedGoogle Scholar
• MUTCHNICK MG, APPELMAN HD, CHUNG HT et al.: Thymosin treatment of chronic hepatitis B: a placebo-controlled pilot trial. Hepatology (1991) 14:409–415.
   PubMed Web of Science ®Google Scholar
• CHIEN RN, LIAW YF, CHEN TC, YEH CT, SHEEN IS: Efficacy of thymosin alpha], in patients with chronic hepatitis B: a randomized, controlled trial. Hepatology (1998) 27:1383–1387.
   PubMed Web of Science ®Google Scholar
• MUTCHNICK MG, LINDSAY KL, SCHIFF ER et al.: Thymosin alpha], treatment of chronic hepatitis B: results of a Phase III multicentre, randomized, double-blind and placebo-controlled study. I Viral Ilepat. (1999) 6:397–403.
   PubMed Web of Science ®Google Scholar
• ZAVAGLIA C, SEVERINI R, TINELLI C et al.: A randomized, controlled study of thymosin-alphal therapy in patients with anti-HBe, HBV-DNA-positive chronic hepatitis B. Dig. Dis. Sci. (2000) 45:690–696.
   PubMed Web of Science ®Google Scholar
• ZHUANG L, YOU J, TANG BZ et al.: Preliminary results of thymosin-a1 versus interferon-alpha-treatment in patients with HBeAg negative and serum HBV DNA positive chronic hepatitis B. World Gastiventerol. (2001) 7:407–410.
   PubMed Web of Science ®Google Scholar
• YOU J, ZHUANG L, TANG BZ et al.: A randomized controlled clinical trial on the treatment of thymosin al versus interferon-alpha in patients with hepatitis B. World Gastiventerol. (2001)7:411–414.
   PubMed Web of Science ®Google Scholar
• ARASE Y, TSUBOTA A, SUZUKI Y et al.: A pilot study of thymosin alpha1 therapy for chronic hepatitis B patients. Intern. Med. (2003) 42:941–946.
   PubMed Web of Science ®Google Scholar
• ANDREONE P, CURSARO C, GRAMENZI A et al.: A randomized controlled trial of thymosin-alphal versus interferon alfa treatment in patients with hepatitis B e antigen antibody-andhepatitis B virus DNA-positive chronic hepatitis B. Hepatology (1996) 24:774–777.
   PubMed Web of Science ®Google Scholar
• CHAN HL, TANG JL, TAM W, SUNG JJ: The efficacy of thymosin in the treatment of chronic hepatitis B virus infection: a meta-analysis. Aliment. Pharmacol. Pier. (2001) 15:1899–1905.
   PubMed Web of Science ®Google Scholar
• •A meta-analysis on the efficacy of thymosin in the treatment against HBV.
   Google Scholar
• SHAW T, LOCARNINI S: Combination chemotherapy for hepatitis B virus: the final solution? Hepatology (2000) 32:430–432.
   PubMed Web of Science ®Google Scholar
• SANTANTONIO T, ANNA NG, SINISI E et al.: Lamivudine/interferon combination therapy in anti-HBe positive chronic hepatitis B patients: a controlled pilot study. J. Hepatol. (2002) 36:799–804.
   PubMed Web of Science ®Google Scholar
• SCHIFF ER, DIENSTAG JL, KARAYALCIN S et al.: Lamivudine and 24 weeks of lamivudine/interferon combination therapy for hepatitis B e antigen-positive chronic hepatitis B in interferon nonresponders. Hepatol. (2003) 38:818–826.
   Web of Science ®Google Scholar
• DIMOU E, ALEXOPOULOU A, PAPADIMITROPOULOS V, PAPATHEODORIDIS GV, HADZIYANNIS SJ: Effect of a 6-month interferon-alfa (IFNa) course on efficacy of long-term lamivudine (LAM) monotherapy in patients with HBeAg-negative [HBeAg (-)] chronic hepatitis B. Hepatol. (2003) 38\(Suppl. 2):136.
   Web of Science ®Google Scholar
• MANESIS EK, PAPATHEODORIDIS GV, ALEXOPOULOU A: Treatment of HBeAg-negative chronic hepatitis B (CHBe-) with sequential lamivudine (LAM) and interferon-alfa (IFN) courses of 12-month duration and a 6-month overlap. Hepatol. (2003) 38\(Suppl. 2):526–527.
   Google Scholar
• SCHALM SW, HEATHCOTE J, CIANCIARA J et al.: Lamivudine and alpha interferon combination treatment of patients with chronic hepatitis B infection: a randomised trial. Gut (2000) 46:562–568.
   PubMed Web of Science ®Google Scholar
• BARBARO G, ZECHINI F,PELLICELLI AM et al.: Long-term efficacy of interferon alpha-2b and lamivudine in combination compared to lamivudine monotherapy in patients with chronic hepatitis B. An Italian multicenter,randomized trial. Hepatol. (2001) 35:406–411.
   Web of Science ®Google Scholar
• SHARMA BC, SARIN SK, KUMAR S et al.: Higher efficacy of sequential tehrapy of lamivudine and interferon-a (IFN) versus lamivudine monotherapy in patients with HBeAg positive chronic hepatitis B (CHB): a prospective randomized controlled trial.Hepatol. (2004) 40\(Suppl. 1):131.
   Google Scholar
• CHAN HLY, LEUNG NWY, HUI AY et al.: A randomized trial of peginterferon alfa-26 and lamivudine combination treatment versus lamivudine monotherapy in Chinese patients with HBeAg-positive chronic hepatitis B. Hepatol. (2004) 40\(Suppl. 1):125–126.
   PubMed Web of Science ®Google Scholar
• VAN ZONNEVELD M, HANSEN BE, NIESTERS HGM, DE MAN RA, SCHALM SW, JANSSEN HLA: Viral dynamics during PEG-interferon alone and in combination with lamivudine. I Hepatol. (2004) 40\(Suppl. 0:132.
   Google Scholar
• LAU GK, TSIANG M, HOU J et al.: Combination therapy with lamivudine and famciclovir for chronic hepatitis B-infected Chinese patients: a viral dynamics study. Hepatology (2000) 32:394–399.
   PubMed Web of Science ®Google Scholar
• SUNG JJY, LAI JY, ZEUZEM S et al.: A randomised double-blind Phase II study of lamivudine (LAM) compared to lamivudine plus adefovir dipivoxil (ADV) for treatment naive patients with chronic hepatitis B (CHB): week 52 analysis. Hepatol. (2003) 38\(Suppl. 2):25–26.
   PubMed Web of Science ®Google Scholar
• AKBAR SM, FURUKAWA S, HORIIKE N, ONJI M: Vaccine therapy for hepatitis B virus carrier. Cup: Drug Targets Infect. Disord. (2004) 4:93–101.
   PubMedGoogle Scholar
• HELVACI M, KIZILGUNESLER A, KASIRGA E, OZBAL E, KUZU M, SOZEN G: Efficacy of hepatitis B vaccination and interferon-alpha-2b combination therapy versus interferon-alpha-26 monotherapy in children with chronic hepatitis B. Gastiventerol. Hepatol. (2004) 19:785–791.
   PubMed Web of Science ®Google Scholar
• RASI G, MUTCHNICK MG, DI VIRGILIO D et al.: Combination low-dose lymphoblastoid interferon and thymosin alpha 1 therapy in the treatment of chronichepatitis B.Hepat. (1996)3:191-196. 151. SARUC M, YUCEYAR H, KUCUKMETIN N, DEMIR MA, KANDILOGLU AR: Combination thymosin-alpha 1 and interferon-alpha 2bin the treatment of anti-HBe-positive chronic hepatitis B in Turkey. Hepatogastroenterology (2002) 49:798–802.
   PubMed Web of Science ®Google Scholar
• LAU GK, NANJI A, HOU J et al.: Thymosin-alphal and famciclovir combination therapy activates T-cell response in patients with chronic hepatitis B virus infection in immune-tolerant phase. J. Viral Hepat. (2002) 9:280–287.
   PubMed Web of Science ®Google Scholar
• SARUC M, OZDEN N, TURKEL N et al.: Long-term outcomes of thymosin-alpha 1 and interferon alpha-2b combination therapy in patients with hepatitis B e antigen (HBeAg) negative chronic hepatitis B. I Pharm. Sci. (2003) 92:1386–1395.
   PubMed Web of Science ®Google Scholar
• DAHMEN A, HERZOG-HAUFF S, BOCHER WO, GALLE PR, LOHR HF: Clinical and immunological efficacy of intredermal vaccine plus lamivudine with or without interleukin-2 in patients with chronic hepatitis B. J. Med. Viral. (2002) 66:452–460.
   PubMed Web of Science ®Google Scholar
• MENNE S, RONEKER CA, KORBA BE, GERIN JL, TENNANT BC, COTE PJ: Immunization with surface antigen vaccine alone and after treatment with 1-(2-fluoro-5-methyl-beta-L-arabinofuranosyl)-uracil (L-FMAU) breaks humoral and cell-mediated immune tolerance in chronic woodchuck hepatitis virus infection. Viral. (2002) 76:5305–5314.
   PubMed Web of Science ®Google Scholar
• MENNE S, RONEKER CA, TENNANT BC, KORBA BE, GERIN JL, COTE PJ: Immunogenic effects of woodchuck hepatitis virus surface antigen vaccine in combination with antiviral therapy: breaking of humoral and cellular immune tolerance in chronic woodchuck hepatitis virus infection. Inter virology (2003) 45:237–250.
   Google Scholar
• JACQUARD AC, NASSAL M, PICHOUD C et al.: Effect of a combination of clevudine and emtricitabine with adenovirus-mediated delivery of gamma interferon in the woodchuck model of hepatitis B virus infection. Antimicrob. Agents Chemother. (2004) 48:2683–2692.
   PubMed Web of Science ®Google Scholar
• HEATHCOTE E, MCHUTCHINSON J, LEE S et al.: A pilot study of the CY-1899 T-cell vaccine in subjects chronically infected with hepatitis B virus. Hepatology (1999) 30:531–536.
   PubMed Web of Science ®Google Scholar
• DAVIS HL, MICHEL M-L, WHALEN RG: DNA based immunization for hepatitis B induces continuous secretionof antigen and high levels of circulating antibody. Hum. Malec. Genet. (1993) 2:1847–1851.
   Web of Science ®Google Scholar
• MAILLIARD ME, GOLLAN JL: Suppressing hepatitis B without resistance — so far, so good. N. Engl. J. Med. (2003) 348:848–850.
   PubMed Web of Science ®Google Scholar
• KEEFFE EB, DIETERICH DT, HAN SH et al.: A treatment algorithm for the management of chronic hepatitis B virus infection in the United States. Clin. Gastroenterol Hepatol (2004) 2:87–106.
   PubMed Web of Science ®Google Scholar